Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.
Follow-Up Questions
Who is the CEO of WuXi Biologics (Cayman) Inc?
Dr. Zhisheng Chen is the Chief Executive Officer of WuXi Biologics (Cayman) Inc, joining the firm since 2014.
What is the price performance of WXXWY stock?
The current price of WXXWY is $10, it has decreased 0% in the last trading day.
What are the primary business themes or industries for WuXi Biologics (Cayman) Inc?
WuXi Biologics (Cayman) Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is WuXi Biologics (Cayman) Inc market cap?
WuXi Biologics (Cayman) Inc's current market cap is $20.3B
Is WuXi Biologics (Cayman) Inc a buy, sell, or hold?
According to wall street analysts, 27 analysts have made analyst ratings for WuXi Biologics (Cayman) Inc, including 9 strong buy, 17 buy, 6 hold, 0 sell, and 9 strong sell
